Cwm LLC Sells 9,512 Shares of Quanterix Co. (NASDAQ:QTRX)

Cwm LLC lessened its stake in shares of Quanterix Co. (NASDAQ:QTRX) by 5.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 175,826 shares of the company’s stock after selling 9,512 shares during the period. Cwm LLC owned approximately 0.46% of Quanterix worth $4,807,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Gotham Asset Management LLC bought a new position in Quanterix during the 3rd quarter valued at approximately $423,000. Lord Abbett & CO. LLC purchased a new stake in Quanterix during the 3rd quarter valued at $27,744,000. Vanguard Group Inc. boosted its stake in Quanterix by 1.4% during the 3rd quarter. Vanguard Group Inc. now owns 1,997,295 shares of the company’s stock valued at $54,207,000 after purchasing an additional 26,660 shares during the last quarter. Emerald Mutual Fund Advisers Trust boosted its stake in Quanterix by 353.4% during the 3rd quarter. Emerald Mutual Fund Advisers Trust now owns 313,044 shares of the company’s stock valued at $8,496,000 after purchasing an additional 243,994 shares during the last quarter. Finally, Emerald Advisers LLC purchased a new stake in Quanterix during the 3rd quarter valued at $10,462,000. Institutional investors own 86.48% of the company’s stock.

Analyst Ratings Changes

Separately, Scotiabank increased their target price on Quanterix from $30.00 to $32.00 and gave the company a “sector outperform” rating in a research note on Monday, March 4th. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Quanterix presently has an average rating of “Buy” and a consensus price target of $32.00.

Insider Transactions at Quanterix

In other news, Director Laurie J. Olson sold 1,500 shares of the firm’s stock in a transaction on Wednesday, February 14th. The stock was sold at an average price of $24.35, for a total value of $36,525.00. Following the transaction, the director now directly owns 15,238 shares in the company, valued at approximately $371,045.30. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 8.20% of the company’s stock.

Quanterix Stock Performance

QTRX stock opened at $16.10 on Wednesday. Quanterix Co. has a 1 year low of $11.39 and a 1 year high of $29.70. The stock’s fifty day moving average price is $23.49 and its 200-day moving average price is $23.58.

Quanterix (NASDAQ:QTRX) last released its quarterly earnings results on Thursday, February 29th. The company reported ($0.33) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.05). The firm had revenue of $31.55 million during the quarter, compared to analysts’ expectations of $27.92 million. Quanterix had a negative return on equity of 9.15% and a negative net margin of 26.42%. On average, sell-side analysts expect that Quanterix Co. will post -1.04 EPS for the current year.

About Quanterix

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.